[Thrombolytic therapy in acute myocardial infarct].
Bode
C
C
Medizinische Klinik III (Kardiologie, Pulmologie und Angiologie), Universität Heidelberg.
Baumann
H
H
von Hodenberg
E
E
Kübler
W
W
D016255:Anistreplase / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004792:Enzyme Precursors / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000627:therapeutic use; D011994:Recombinant Proteins; D012770:Shock, Cardiogenic / Q000188:drug therapy; D013300:Streptokinase / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D004792:Enzyme Precursors; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D016255:Anistreplase; D013300:Streptokinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase
Thrombolytische Therapie des akuten Myokardinfarktes.